Centogene (CNTG)

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Its goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using its extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on its real-world data repository with over 3.6 billion weighted data points from approximately 595,000 patients representing over 120 different countries as of September 30, 2020. The Company's platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve its pharmaceutical partners' ability to bring orphan drugs to the market. As of September 30, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

Company profile

Ticker

CNTG

Exchange

NASDAQ

Website

www.centogene.com

CEO

Arndt Rolfs

Incorporated

Netherlands

Location

Germany

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corp. Of America • Akumin • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Enzo Biochem ...

Former names

Centogene B.V.

SEC CIK

0001757097

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CNTG stock data

1M 1Y 5Y

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Monday

13 Jun 22

During Monday's trading, 1214 companies set new 52-week lows.

CENTOGENE and Agios Expand Partnership For Clinical Development Of PYRUKYND To Treat Children With Rare Blood Disease

13 Jun 22

Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports

Stocks That Hit 52-Week Lows On Friday

3 Jun 22

During Friday's trading, 69 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

2 Jun 22

Stocks That Hit 52-Week Lows On Thursday

26 May 22

Press releases

From Benzinga Pro

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

13 Jun 22

Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE's genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise

CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework

25 May 22

CentoCloud, CENTOGENE's cloud-based Software as a Service (SaaS) platform, is CE-marked under the In Vitro Diagnostics Directive (98/79/EC)CE-marking is required for all in vitro diagnostic (IVD) devices to be placed in

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

23 May 22

Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE's differentiated diagnostic expertise with testing performed in over 650,000

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

19 May 22

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

28 Apr 22

Calendar

31 Mar 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart CNTG financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Centogene earnings reports.

Institutional ownership, Q4 2021

CNTG institutional ownership history Ownership history

38.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	19	-47.4%
Opened positions	0	0
Closed positions	9	6	+50.0%
Increased positions	3	6	-50.0%
Reduced positions	5	8	-37.5%

13F shares	Current	Prev Q	Change
Total value	69.93M	87.64M	-20.2%
Total shares	8.49M	8.81M	-3.6%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
DPE Deutsche Private Equity Gesellschaft mbH	6.04M	$57.1M	0.0%
Platinum Investment Management	2.28M	$11.91M	+18.4%
Acadian Asset Management	70.73K	$366K	+16.2%
Renaissance Technologies	48.47K	$253K	-13.8%
BLK Blackrock	21.42K	$111K	-5.0%
NTRS Northern Trust	13.45K	$70K	-1.2%
Geode Capital Management	11.16K	$57K	-0.1%
JPM JPMorgan Chase & Co.	7.29K	$37K	+1026.6%
Meeder Asset Management	5.17K	$27K	-0.6%
BAC Bank Of America	309	$1K	0.0%

Largest transactions	Shares	Bought/sold	Change
Millennium Management	0	-498.19K	EXIT
Platinum Investment Management	2.28M	+354.07K	+18.4%
WFC Wells Fargo & Co.	0	-108.74K	EXIT
Ergoteles	0	-38.66K	EXIT
HRT Financial	0	-17.81K	EXIT
MS Morgan Stanley	0	-14.51K	EXIT
Acadian Asset Management	70.73K	+9.85K	+16.2%
Renaissance Technologies	48.47K	-7.73K	-13.8%
JPM JPMorgan Chase & Co.	7.29K	+6.64K	+1026.6%
Optiver Holding B.V.	0	-2K	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.